Skip to content

Trial Summary

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Acronym:

KRYSTAL 10

ACTRN/NCT /ethics:

NCT04793958

Scientific title:

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Sponsor / Cooperative group:

Mirati Therapeutics Inc

Trial & Patient Characteristics

Cancer TypeBowel and colon
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexAll
Tumour Stream Advanced Colorectal Cancer with KRAS G12C mutation
Cancer StageLocally Advanced, Metastatic or Widespread
Anticipated Start Date2021-03-15
Anticipated End Date2023-09-30

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusNot Yet Recruiting